Exelixis, Inc. (NASDAQ:EXEL) Expected to Post Quarterly Sales of $378.80 Million – Defense World

Equities analysts expect Exelixis, Inc. (NASDAQ:EXEL Get Rating) to report sales of $378.80 million for the current quarter, Zacks reports. Six analysts have made estimates for Exelixis earnings, with the highest sales estimate coming in at $475.40 million and the lowest estimate coming in at $344.39 million. Exelixis posted sales of $270.23 million in the same quarter last year, which suggests a positive year over year growth rate of 40.2%. The company is expected to issue its next earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Exelixis will report full-year sales of $1.69 billion for the current year, with estimates ranging from $1.53 billion to $2.01 billion. For the next financial year, analysts anticipate that the business will post sales of $1.92 billion, with estimates ranging from $1.84 billion to $2.09 billion. Zacks sales averages are an average based on a survey of research analysts that that provide coverage for Exelixis.

Exelixis (NASDAQ:EXEL Get Rating) last posted its quarterly earnings data on Thursday, February 17th. The biotechnology company reported $0.29 EPS for the quarter, topping the Thomson Reuters consensus estimate of $0.07 by $0.22. Exelixis had a return on equity of 11.17% and a net margin of 16.10%. The company had revenue of $451.14 million during the quarter, compared to analyst estimates of $357.17 million.

NASDAQ:EXEL opened at $22.34 on Friday. Exelixis has a 12 month low of $15.50 and a 12 month high of $25.77. The stock has a 50 day moving average of $21.75 and a two-hundred day moving average of $19.70. The firm has a market cap of $7.15 billion, a P/E ratio of 31.46, a price-to-earnings-growth ratio of 0.71 and a beta of 0.79.

In other Exelixis news, EVP Patrick J. Haley sold 60,000 shares of the companys stock in a transaction on Thursday, February 3rd. The stock was sold at an average price of $17.91, for a total transaction of $1,074,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jack L. Wyszomierski sold 6,696 shares of the companys stock in a transaction on Monday, April 4th. The stock was sold at an average price of $23.00, for a total value of $154,008.00. Following the transaction, the director now owns 273,192 shares in the company, valued at $6,283,416. The disclosure for this sale can be found here. Insiders sold 205,229 shares of company stock worth $4,017,116 over the last quarter. 3.30% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Jefferies Group LLC lifted its stake in Exelixis by 49.2% during the third quarter. Jefferies Group LLC now owns 69,000 shares of the biotechnology companys stock worth $1,459,000 after purchasing an additional 22,739 shares in the last quarter. BlackRock Inc. raised its stake in shares of Exelixis by 2.0% in the third quarter. BlackRock Inc. now owns 31,907,047 shares of the biotechnology companys stock valued at $674,514,000 after acquiring an additional 612,104 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Exelixis by 31.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,639 shares of the biotechnology companys stock valued at $798,000 after acquiring an additional 10,327 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Exelixis by 32.7% in the third quarter. Squarepoint Ops LLC now owns 359,712 shares of the biotechnology companys stock valued at $7,604,000 after acquiring an additional 88,635 shares in the last quarter. Finally, LPL Financial LLC raised its stake in shares of Exelixis by 70.7% in the third quarter. LPL Financial LLC now owns 63,251 shares of the biotechnology companys stock valued at $1,337,000 after acquiring an additional 26,188 shares in the last quarter. Institutional investors own 82.80% of the companys stock.

About Exelixis (Get Rating)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Exelixis, Inc. (NASDAQ:EXEL) Expected to Post Quarterly Sales of $378.80 Million – Defense World

Categories

Archives

Recommended Sites

Contact Us

Recent Posts